Posted by Michael Wonder on 03 Oct 2025
Alto Neuroscience receives FDA fast track designation for ALTO-101 for the treatment of cognitive impairment associated with schizophrenia
3 October 2025 - Alto Neuroscience today announced that the US FDA has granted fast track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.
There are currently no approved treatments for cognitive impairment associated with schizophrenia, a core feature of schizophrenia that severely impacts daily functioning and quality of life for millions of patients.
